marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-12-2024
Protara Therapeutics Balance Sheet 2011-2024 | TARA
Annual Balance Sheet Protara Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-34.1 M | -17.7 M | -28.5 M | -168 M | -6.18 M | -19.4 M | -21.2 M | -36.4 M | -40 M | -68.8 M | - | - | - |
Long Term Debt |
4.48 M | 5.47 M | 6.38 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
983 K | 917 K | 855 K | 88 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 999 K | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
6.15 M | 5.74 M | 4.3 M | 2.92 M | 583 K | 3.08 M | 9.24 M | 5.08 M | 4.13 M | 2.34 M | - | - | - |
Total Liabilities |
10.6 M | 11.2 M | 10.7 M | 3.91 M | 583 K | 3.08 M | 9.24 M | 5.08 M | 4.13 M | 2.34 M | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-200 M | -160 M | -94 M | -46.8 M | -225 M | -210 M | -190 M | -160 M | -131 M | -110 M | - | - | - |
Total Assets |
79 M | 113 M | 173 M | 203 M | 6.98 M | 23.5 M | 44 M | 43.5 M | 67.5 M | 84.8 M | - | - | - |
Cash and Cash Equivalents |
39.6 M | 24.1 M | 35.7 M | 169 M | 6.18 M | 19.4 M | 21.2 M | 36.4 M | 40 M | 68.8 M | 2.79 M | 2.41 M | - |
Book Value |
68.3 M | 102 M | 162 M | 199 M | 6.39 M | 20.4 M | 34.7 M | 38.4 M | 63.4 M | 82.5 M | - | - | - |
Total Shareholders Equity |
68.3 M | 102 M | 162 M | 199 M | -2.13 M | 20.4 M | 34.7 M | 38.4 M | 63.4 M | 82.5 M | -101 M | -86.7 M | - |
All numbers in USD currency
Quarterly Balance Sheet Protara Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
3.66 M | 3.95 M | 4.23 M | 4.48 M | 4.74 M | 4.98 M | 5.23 M | 5.47 M | 5.7 M | 5.93 M | 6.16 M | 6.38 M | 6.6 M | 6.82 M | 974 K | 999 K | 999 K | 999 K | 999 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
12.3 M | 9.6 M | 9.73 M | 10.6 M | 11.5 M | 9.92 M | 11.6 M | 11.2 M | 9.41 M | 9.43 M | 9.02 M | 10.7 M | 10.3 M | 10.5 M | 4.29 M | 3.91 M | 3.91 M | 3.91 M | 3.91 M | 3.35 M | 3.35 M | 3.35 M | 3.35 M | 3.08 M | 3.08 M | 3.08 M | 3.08 M | 9.24 M | 9.24 M | 9.24 M | 9.24 M | 5.08 M | 5.08 M | 5.08 M | 5.08 M | 4.13 M | 4.13 M | 4.13 M | 4.13 M | 2.34 M | 2.34 M | 2.34 M | 2.34 M | 9.77 M | 9.77 M | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.95 M | 2.95 M | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-232 M | -221 M | -211 M | -200 M | -190 M | -180 M | -169 M | -160 M | -121 M | -113 M | -105 M | -94 M | -83.8 M | -73 M | -60.2 M | -46.8 M | -46.8 M | -46.8 M | -46.8 M | -12.8 M | -12.8 M | -12.8 M | -12.8 M | -210 M | -210 M | -210 M | -210 M | -190 M | -190 M | -190 M | -190 M | -160 M | -160 M | -160 M | -160 M | -131 M | -131 M | -131 M | -131 M | -110 M | -110 M | -110 M | -110 M | -101 M | -101 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
94.1 M | 102 M | 68.1 M | 79 M | 88.5 M | 95.1 M | 106 M | 113 M | 149 M | 155 M | 161 M | 173 M | 181 M | 189 M | 192 M | 203 M | 203 M | 203 M | 203 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 44 M | 44 M | 44 M | 44 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M | 67.5 M | 67.5 M | 67.5 M | 67.5 M | 84.8 M | 84.8 M | 84.8 M | 84.8 M | 5.66 M | 5.66 M | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
51.8 M | 89.6 M | 52.2 M | 39.6 M | 34.5 M | 34.7 M | 21.8 M | 24.1 M | 48.2 M | 34.6 M | 26.2 M | 35.7 M | 40.7 M | 47.6 M | 58.2 M | 169 M | 169 M | 169 M | 169 M | 564 K | 564 K | 564 K | 564 K | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 36.4 M | 36.4 M | 36.4 M | 36.4 M | 40 M | 40 M | 40 M | 40 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 2.79 M | 2.79 M | - | - | 2.41 M | - | - | - | 3.27 M | - | - | - |
Book Value |
81.8 M | 92 M | 58.4 M | 68.3 M | 77 M | 85.2 M | 94.8 M | 102 M | 139 M | 145 M | 152 M | 162 M | 170 M | 178 M | 188 M | 199 M | 199 M | 199 M | 199 M | -2.13 M | -2.13 M | -2.13 M | -2.13 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 34.7 M | 34.7 M | 34.7 M | 34.7 M | 38.4 M | 38.4 M | 38.4 M | 38.4 M | 63.4 M | 63.4 M | 63.4 M | 63.4 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | -4.11 M | -4.11 M | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
81.8 M | 92 M | 58.4 M | 68.3 M | 77 M | 85.2 M | 94.8 M | 102 M | 139 M | 145 M | 152 M | 162 M | 170 M | 178 M | 188 M | 199 M | 199 M | 199 M | 199 M | -2.13 M | -2.13 M | -2.13 M | -2.13 M | 4.78 M | 20.4 M | 20.4 M | 20.4 M | 34.7 M | 34.7 M | 34.7 M | 34.7 M | 38.4 M | 38.4 M | 38.4 M | 38.4 M | 63.4 M | 63.4 M | 63.4 M | 63.4 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | -101 M | -101 M | - | - | -86.7 M | - | - | - | -72.7 M | - | - | - |
All numbers in USD currency